All data are based on the daily closing price as of December 3, 2024
l

Lumosa Therapeutics

6535.TWO
8.99 USD
-0.98
-9.83%

Overview

Last close
8.99 usd
Market cap
1.48B usd
52 week high
12.06 usd
52 week low
1.81 usd
Target price
7.5 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
1123.2059
Price/Book Value
51.5647
Enterprise Value
1.81B usd
EV/Revenue
1559.7421
EV/EBITDA
N/A

Key financials

Revenue TTM
1.47M usd
Gross Profit TTM
N/A usd
EBITDA TTM
-10.30M usd
Earnings per Share
-0.07 usd
Dividend
N/A usd
Total assets
1.60B usd
Net debt
-279.44M usd

About

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.
  • Symbol
    6535.TWO
  • Exchange
    TWO
  • Isin
    N/A
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Mr. Rong-Jin Lin Ph.D.
  • Headquarter
    Taipei
  • Web site
    https://www.lumosa.com.tw
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top